CD33 and non-small cell lung carcinoma: Interestingly, a novel subset of Lin− HLA-DR− CD33+ CD11b+ CD14+ CD15+ has been reported in a study of non-small cell lung cancer (NSCLC), in which the CD14+ CD15+ population was revealed to have a satisfactory prognostic value in untreated patients [16].